Entero Therapeutics, Inc.

NasdaqCM:ENTO Voorraadrapport

Marktkapitalisatie: US$2.2m

Entero Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Entero Therapeutics has a total shareholder equity of $70.8M and total debt of $177.6K, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are $86.3M and $15.5M respectively.

Belangrijke informatie

0.3%

Verhouding schuld/eigen vermogen

US$177.56k

Schuld

Rente dekkingsration/a
ContantUS$662.48k
AandelenUS$70.80m
Totaal verplichtingenUS$15.49m
Totaal activaUS$86.29m

Recente financiële gezondheidsupdates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

Jun 07

AzurRx BioPharma: An Assessment

May 02

AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio

Jan 31

Analyse van de financiële positie

Kortlopende schulden: ENTO's short term assets ($84.4M) exceed its short term liabilities ($15.4M).

Langlopende schulden: ENTO's short term assets ($84.4M) exceed its long term liabilities ($101.0K).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ENTO has more cash than its total debt.

Schuld verminderen: ENTO's debt to equity ratio has reduced from 64.5% to 0.3% over the past 5 years.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ENTO has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: ENTO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.1% each year


Ontdek gezonde bedrijven